This report covers pediatric and adult preventive vaccine products and provides an analysis of therapeutic vaccines for cancer treatment. In assessing the market for vaccine products, Kalorama Information provides sales data for the 2001-2003 historical years, the 2004 base year, and the 2001 through 2010 forecast years. Revenues are expressed in terms of manufacturers’ annual sales and in current U.S. dollars.
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and e-mail correspondence were the primary method of gathering information. For the purpose of this study, Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
Pediatric vaccines include the following:
- Combination vaccines
- Diphtheria-tetanus-pertussis (DTP) and diphtheria-tetanus-acellular pertussis (DTaP)
- Hepatits A; Hepatitis B
- Measles-mumps-rubella (MMR)
Adult vaccines include the following:
- Hepatitis A; Hepatitis B
- Travel; DT; others
In addition to preventive vaccines, the emerging area of therapeutic vaccines for the treatment of cancer is covered, including current revenues from the handful of products now on the market, plus a forecast of revenues for products likely to see approval through 2008.